📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

U.S. to pay $1 billion for 100 million doses of Johnson & Johnson's COVID-19 vaccine candidate

Published 08/05/2020, 09:09 AM
Updated 08/05/2020, 11:20 AM
© Reuters. FILE PHOTO: A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration
SASY
-
PFE
-
JNJ
-
REGN
-
BNTX
-

By Michael Erman

(Reuters) - The United States government will pay Johnson & Johnson (N:JNJ) over $1 billion for 100 million doses of its potential coronavirus vaccine, as it stocks up on vaccine and drugs in an attempt to tame the pandemic.

The latest contract is priced at roughly $10 per vaccine dose produced by J&J, or around $14.50 per dose, including a previous $456 million the U.S. government promised to J&J for vaccine development in March. That compares with the $19.50 per dose that the U.S. is paying for the vaccine being developed by Pfizer Inc (N:PFE) and German biotech BioNTech SE (F:22UAy).

J&J is studying both one and two-dose regimens of its vaccine. Pfizer and BioNTech's candidate would require two doses per person treated. The drugmaker said on Wednesday it would deliver the vaccine to the Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorization by the U.S. Food and Drug Administration (FDA).

The U.S. government may also purchase an additional 200 million doses under a subsequent agreement. J&J did not disclose that deal's value.

As the race for vaccines and treatments for COVID-19 intensifies, the U.S. government has been signing deals to buy them through its Operation Warp Speed program. Other drugmakers who have signed deals include Sanofi SA (PA:SASY) and Regeneron Inc. (N:REGN)

This is J&J's first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been reached.

J&J's investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early-stage study.

There are currently no approved vaccines for COVID-19. More than 20 are in clinical trials.

Shares of J&J were up around 1 percent in early trading on the New York Stock Exchange.

© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the NYSE in New York

(This story corrects size of previous deal with BARDA in paragraph two)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.